ArticleInterdisciplinary sciences, computational life sciences2025
A Multi-View Feature-Based Interpretable Deep Learning Framework for Drug-Drug Interaction Prediction.
Article in Interdisciplinary sciences, computational life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Computational approaches for drug-drug interaction prediction: a systematic review of data sources, modeling strategies, and evaluation frameworks.Frontiers in pharmacology · 2026Pooled it
- Graph-Based Machine Learning for Predicting Drug-Drug Interactions: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Mol2Image: an enhanced DDI prediction framework leveraging drug molecular descriptors.BMC bioinformatics · 2026Article
- MHAFR-DDI: a multimodal hierarchical attention fusion and relation-aware architecture for drug-drug interaction event prediction.Briefings in bioinformatics · 2026Article
- Artificial Intelligence Models and Tools for the Assessment of Drug-Herb Interactions.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Drug-drug interactions (DDIs) can result in deleterious consequences when patients take multiple medications simultaneously, emphasizing the critical need for accurate DDI prediction. Computational methods for DDI prediction have garnered recent attention. However, current approaches concentrate solely on single-view features, such as atomic-view or substructure-view features, limiting predictive capacity. The scarcity of research on interpretability studies based on multi-view features is crucial for tracing interactions. Addressing this gap, we present MI-DDI, a multi-view feature-based interpretable deep learning framework for DDI. To fully extract multi-view features, we employ a Message Passing Neural Network (MPNN) to learn atomic features from molecular graphs generated by RDkit, and transformer encoders are used to learn substructure-view embeddings from drug SMILES simultaneously. These atomic-view and substructure-view features are then amalgamated into a holistic drug embedding matrix. Subsequently, an intricately designed interaction module not only establishes a tractable path for understanding interactions but also directly informs the construction of weight matrices, enabling precise and interpretable interaction predictions. Validation on the BIOSNAP dataset and DrugBank dataset demonstrates MI-DDI's superiority. It surpasses the current benchmarks by a substantial average of 3% on BIOSNAP and 1% on DrugBank. Additional experiments underscore the significance of atomic-view information for DDI prediction and confirm that our interaction module indeed learns more effective information for DDI prediction. The source codes are available at https://github.com/ZihuiCheng/MI-DDI .
Indexed as
Identifiers
39899225What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.